CN109053477A - 一种仲丁灵半抗原与抗原的制备方法及应用 - Google Patents
一种仲丁灵半抗原与抗原的制备方法及应用 Download PDFInfo
- Publication number
- CN109053477A CN109053477A CN201811104606.4A CN201811104606A CN109053477A CN 109053477 A CN109053477 A CN 109053477A CN 201811104606 A CN201811104606 A CN 201811104606A CN 109053477 A CN109053477 A CN 109053477A
- Authority
- CN
- China
- Prior art keywords
- butralin
- haptens
- antigen
- liquid
- adds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SPNQRCTZKIBOAX-UHFFFAOYSA-N Butralin Chemical compound CCC(C)NC1=C([N+]([O-])=O)C=C(C(C)(C)C)C=C1[N+]([O-])=O SPNQRCTZKIBOAX-UHFFFAOYSA-N 0.000 title claims abstract description 85
- 239000000427 antigen Substances 0.000 title claims abstract description 37
- 102000036639 antigens Human genes 0.000 title claims abstract description 37
- 108091007433 antigens Proteins 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 claims abstract description 16
- 241000208125 Nicotiana Species 0.000 claims abstract description 10
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims abstract description 10
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 9
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 9
- 238000002965 ELISA Methods 0.000 claims abstract description 8
- 238000001514 detection method Methods 0.000 claims abstract description 8
- 238000012360 testing method Methods 0.000 claims abstract description 6
- 239000000084 colloidal system Substances 0.000 claims abstract description 4
- 235000013305 food Nutrition 0.000 claims abstract description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000010931 gold Substances 0.000 claims abstract description 4
- 229910052737 gold Inorganic materials 0.000 claims abstract description 4
- 238000010998 test method Methods 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims description 34
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 108010058846 Ovalbumin Proteins 0.000 claims description 10
- 229940092253 ovalbumin Drugs 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 235000019441 ethanol Nutrition 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 150000001718 carbodiimides Chemical class 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- AVMSWPWPYJVYKY-UHFFFAOYSA-N 2-Methylpropyl formate Chemical compound CC(C)COC=O AVMSWPWPYJVYKY-UHFFFAOYSA-N 0.000 claims description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 3
- FARWKNMCTNKCLL-UHFFFAOYSA-N C(C)(=O)O.ClC1=CC(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-] Chemical compound C(C)(=O)O.ClC1=CC(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-] FARWKNMCTNKCLL-UHFFFAOYSA-N 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 229940098773 bovine serum albumin Drugs 0.000 claims description 3
- 238000005660 chlorination reaction Methods 0.000 claims description 3
- 238000005352 clarification Methods 0.000 claims description 3
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229960001866 silicon dioxide Drugs 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 229960002317 succinimide Drugs 0.000 claims description 3
- 108010017384 Blood Proteins Proteins 0.000 claims description 2
- 102000004506 Blood Proteins Human genes 0.000 claims description 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
- 108060003552 hemocyanin Proteins 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims 3
- LNVWRBNPXCUYJI-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrazol-4-amine Chemical compound CC1=NNC(C)=C1N LNVWRBNPXCUYJI-UHFFFAOYSA-N 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 230000000890 antigenic effect Effects 0.000 abstract description 2
- 238000001914 filtration Methods 0.000 abstract description 2
- 238000004458 analytical method Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 238000002649 immunization Methods 0.000 description 7
- 230000003053 immunization Effects 0.000 description 6
- 239000004009 herbicide Substances 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 239000000575 pesticide Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- LZGUHMNOBNWABZ-UHFFFAOYSA-N n-nitro-n-phenylnitramide Chemical compound [O-][N+](=O)N([N+]([O-])=O)C1=CC=CC=C1 LZGUHMNOBNWABZ-UHFFFAOYSA-N 0.000 description 4
- ZSDSQXJSNMTJDA-UHFFFAOYSA-N trifluralin Chemical compound CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O ZSDSQXJSNMTJDA-UHFFFAOYSA-N 0.000 description 4
- 239000005471 Benfluralin Substances 0.000 description 3
- NEKOXWSIMFDGMA-UHFFFAOYSA-N Isopropalin Chemical compound CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(C)C)C=C1[N+]([O-])=O NEKOXWSIMFDGMA-UHFFFAOYSA-N 0.000 description 3
- SMDHCQAYESWHAE-UHFFFAOYSA-N benfluralin Chemical compound CCCCN(CC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O SMDHCQAYESWHAE-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000005591 Pendimethalin Substances 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- -1 chlopyrifos Chemical compound 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002363 herbicidal effect Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- CHIFOSRWCNZCFN-UHFFFAOYSA-N pendimethalin Chemical compound CCC(CC)NC1=C([N+]([O-])=O)C=C(C)C(C)=C1[N+]([O-])=O CHIFOSRWCNZCFN-UHFFFAOYSA-N 0.000 description 2
- 239000000447 pesticide residue Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- ZOCSXAVNDGMNBV-UHFFFAOYSA-N 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile Chemical compound NC1=C(S(=O)C(F)(F)F)C(C#N)=NN1C1=C(Cl)C=C(C(F)(F)F)C=C1Cl ZOCSXAVNDGMNBV-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- TWFZGCMQGLPBSX-UHFFFAOYSA-N Carbendazim Natural products C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- LPXYXBZAXFTFKH-UHFFFAOYSA-N ClC=1C(=C(C(=NC1)C(=O)O)C(=O)O)Cl Chemical compound ClC=1C(=C(C(=NC1)C(=O)O)C(=O)O)Cl LPXYXBZAXFTFKH-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 239000005899 Fipronil Substances 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- BAFQDKPJKOLXFZ-UHFFFAOYSA-N Paraoxon-methyl Chemical compound COP(=O)(OC)OC1=CC=C([N+]([O-])=O)C=C1 BAFQDKPJKOLXFZ-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- MXWJVTOOROXGIU-UHFFFAOYSA-N atrazine Chemical compound CCNC1=NC(Cl)=NC(NC(C)C)=N1 MXWJVTOOROXGIU-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000010352 biotechnological method Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000006013 carbendazim Substances 0.000 description 1
- JNPZQRQPIHJYNM-UHFFFAOYSA-N carbendazim Chemical compound C1=C[CH]C2=NC(NC(=O)OC)=NC2=C1 JNPZQRQPIHJYNM-UHFFFAOYSA-N 0.000 description 1
- DUEPRVBVGDRKAG-UHFFFAOYSA-N carbofuran Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)C2 DUEPRVBVGDRKAG-UHFFFAOYSA-N 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940013764 fipronil Drugs 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- NNKVPIKMPCQWCG-UHFFFAOYSA-N methamidophos Chemical compound COP(N)(=O)SC NNKVPIKMPCQWCG-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- RLBIQVVOMOPOHC-UHFFFAOYSA-N parathion-methyl Chemical group COP(=S)(OC)OC1=CC=C([N+]([O-])=O)C=C1 RLBIQVVOMOPOHC-UHFFFAOYSA-N 0.000 description 1
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 1
- VXPLXMJHHKHSOA-UHFFFAOYSA-N propham Chemical compound CC(C)OC(=O)NC1=CC=CC=C1 VXPLXMJHHKHSOA-UHFFFAOYSA-N 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002786 root growth Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000004454 trace mineral analysis Methods 0.000 description 1
- FFSJPOPLSWBGQY-UHFFFAOYSA-N triazol-4-one Chemical compound O=C1C=NN=N1 FFSJPOPLSWBGQY-UHFFFAOYSA-N 0.000 description 1
- AMFGTOFWMRQMEM-UHFFFAOYSA-N triazophos Chemical compound N1=C(OP(=S)(OCC)OCC)N=CN1C1=CC=CC=C1 AMFGTOFWMRQMEM-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/04—Formation of amino groups in compounds containing carboxyl groups
- C07C227/06—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid
- C07C227/08—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid by reaction of ammonia or amines with acids containing functional groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/77—Ovalbumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
一种仲丁灵半抗原与抗原的制备方法及应用,其特征在于:所述仲丁灵半抗原是由4‑氯‑3,5‑二硝基苯乙酸与丁胺反应得到;所述仲丁灵抗原是由仲丁灵半抗原与载体蛋白偶联得到。本发明制备的抗原呈现出特异性的仲丁灵抗原决定簇,使得筛选出高特异性的仲丁灵单克隆抗体成为可能。产生的抗体特异性高、灵敏度高,可用于建立酶联免疫吸附测定方法和胶体金试纸快速测定法,从而实现烟草及食品中仲丁灵的快速检测。
Description
技术领域
本发明涉及一种仲丁灵半抗原与抗原的制备方法及应用。属于农药免疫化学技术领域。
背景技术
仲丁灵(Butralin)又名地乐胺、双丁乐灵、硝苯胺灵、比达宁、止芽素,化学名称为N-仲丁基-4-特丁基-2,6-二硝基苯胺,分子式为C14H21N3O4。仲丁灵为二硝基苯胺类除草剂,纯品为橙黄色结晶体,易溶于有机溶剂,而难溶于水,有挥发性,受光后易分解,对人畜等动物类毒性较低。该药为选择性萌前除草剂,其作用与氟乐灵相似。药剂进入植物体后,主要抑制分生组织的细胞分裂,从而抑制杂草的幼芽及幼根生长,导致杂草死亡。仲丁灵可应用于大田作物抑制杂草生长,也可用于水产养殖清除水体中的杂藻,仲丁灵在烟草生产中应用较多,主要用来抑制烟草叶芽生长。国际烟草科学研究合作中心(CORESTA)规定烟草中仲丁灵的指导性残留限量为5 mg/kg。
目前,有关仲丁灵残留检测的研究多集中在气相色谱法、液相色谱法、气相色谱串联质谱法、液相色谱串联质谱等色谱质谱方法。但是由于这些分析方法需要昂贵的大型仪器设备和专业的检测人员、前处理过程复杂、操作繁琐、检测成本高、分析速度慢,难以满足现场监测和大量样本中农药残留量快速筛查的需要。基于抗原抗体特异性识别的免疫分析方法可以定性定量检测样品中的农药残留。这种分析方法对仪器设备要求不高、快速简便,一般无需对样品进行复杂的预处理,灵敏度高、特异性强,对使用人员的专业技术要求不高,容易普及和推广,可满足快速分析检测的需要,尤其适宜现场筛选和大量样品的快速分析。免疫分析为仲丁灵残留研究提供了一个新的分析检测途径。免疫分析目前已成为农药残留分析研究的一个崭新领域,美国化学会将免疫分析与气相色谱、液相色谱共同列为农药残留分析的三大支柱技术。我国农药免疫分析技术研究起步相对较晚,但近年来发展迅速,有关于对硫磷、甲基对硫磷、甲基对氧磷、多菌灵、毒死蜱、三唑磷、氟虫腈、二氯喹啉酸、克百威、三唑酮、甲胺磷、阿特拉津、2甲4氯等农药的人工抗原和高亲和力的特异性抗体的制备及用ELISA法进行样品中痕量农药分析的报道。
本发明属于农药小分子化合物免疫化学和残留分析技术领域,涉及有机合成、免疫化学及生物化学等,依靠免疫学、免疫化学基本原理和生物技术手段,设计、合成小分子目标分析物半抗原,并与载体蛋白质偶联,制备有效人工抗原。制备的抗原可以通过免疫动物制备对小分子分析物特异性识别的抗体,利用抗原抗体的特异性免疫学反应和易被检测识别的标记物的放大作用,定量的检测样品中超微量小分子目标物。半抗原的分子设计与合成是产生特异性抗体和建立农药残留免疫分析方法的关键步骤。人工抗原的制备,包括结合位点、结合方式、载体种类及半抗原与目标分析物质任何结构上的差异,诸如分子大小、形状、成分、构型、构象、极性、电子云密度等在内的拓扑性征,都可能极大的影响着相应抗体的性质。目前关于仲丁灵半抗原及抗原的制备方法尚未见报道。
发明内容
本发明的目的正是基于上述现有技术状况而提供一种仲丁灵半抗原与抗原的制备方法。
本发明的目的是通过以下技术方案来实现的:
一种仲丁灵半抗原的制备方法,是由4-氯-3,5-二硝基苯乙酸与丁胺反应得到,其分子结构式为:
。
具体步骤如下:
取4-氯-3,5-二硝基苯乙酸1.0 g,加50 mL乙醇溶解,加碳酸钠0.45 g,搅拌,加丁胺0.31 g,80℃油浴加热,搅拌3 h,检测,原料基本反应完全;停止反应,冷却到室温,旋蒸,除去乙醇,加80 mL水,用1 mol/L盐酸调节pH值到4,有大量浑浊,加80 mL乙酸乙酯萃取,水洗,上硅胶柱,用体积比为5:1的二氯甲烷/甲醇洗脱分离,得到仲丁灵半抗原产物1.05 g。
所述仲丁灵半抗原可用于制作动物免疫的抗原体系原料。
一种仲丁灵抗原的制备方法,是由所述仲丁灵半抗原与载体蛋白偶联得到。所述仲丁灵抗原为仲丁灵半抗原与载体蛋白的偶联物,所述载体蛋白为甲状腺蛋白、牛血清白蛋白、兔血清蛋白、人血清蛋白、卵清蛋白或血蓝蛋白。
具体步骤如下:
免疫抗原的制备:取仲丁灵半抗原11 mg,加二甲基亚砜(DMSO)0.2 mL溶解,加三乙胺20 μL,搅拌,混匀,加氯甲酸异丁酯6 mg,搅拌2 h,得到半抗原活化液A液;取50 mg牛血清白蛋白(BSA)加0.1 mol/L pH值为7.2的PB缓冲液溶解,得到B液,将A液缓慢滴加到B液中,继续搅拌5 h,停止反应,0.02 mol/L PBS透析3 d,每天换液3次,得到仲丁灵-BSA偶联物,即为免疫原。
包被抗原的制备:取仲丁灵半抗原6 mg,加N,N-二甲基甲酰胺(DMF)0.2 mL溶解,加碳二亚胺(EDC)4.5 mg,搅拌,澄清,加N-琥珀酰亚胺(NHS)2.24 mg,室温搅拌活化2 h,得到A液;取卵清蛋白(OVA)50 mg,加6 mL 0.05 mol/L pH值为7.2的PB缓冲液溶解,得到B液,将A液缓慢滴加到B液中,室温搅拌反应5 h,停止反应,0.02 mol/L PBS透析3 d,每天换液3次,得到仲丁灵-OVA偶联物,即为包被原。
采用所述仲丁灵抗原免疫动物得到的单克隆抗体,可用于建立酶联免疫吸附测定方法和胶体金试纸快速测定法,从而实现烟草及食品中仲丁灵的快速检测。
本发明中合成的仲丁灵半抗原既最大程度的保留了仲丁灵的化学结构,又有合适长度的连接臂,用该半抗原制备的抗原呈现出特异性的仲丁灵抗原决定簇,使得筛选出高特异性的仲丁灵单克隆抗体成为可能。产生的抗体特异性高、灵敏度高,可用于建立酶联免疫吸附测定方法和胶体金试纸快速测定法,从而实现烟草及食品中仲丁灵的快速检测。
附图说明
图1:仲丁灵半抗原合成路线图。
具体实施方式
下面结合具体的实施例来进一步阐述本发明。应理解,这些实施例仅用于说明本发明,而不用来限制本发明的范围。
实施例1 仲丁灵半抗原的制备
1、仲丁灵半抗原的合成(合成路线见附图1)
取4-氯-3,5-二硝基苯乙酸1.00 g,加50 mL乙醇溶解,加碳酸钠0.45 g,搅拌,加丁胺0.31 g,80℃油浴加热,搅拌3 h,检测,原料基本反应完全;停止反应,冷却到室温,旋蒸,除去乙醇,加80 mL水,用1 mol/L盐酸调节pH值到4,有大量浑浊,加80 mL乙酸乙酯萃取,水洗,上硅胶柱,用体积比为5:1的二氯甲烷/甲醇洗脱分离,得到仲丁灵半抗原产物1.05 g,收率92.11%。
2、仲丁灵半抗原的鉴定
核磁鉴定1H NMR(CDCl3, 300MHz)δ:11.01(1H, d, J=0.000),8.281(1H, d, J=0.000),4.011(1H, tq, J=6.914, J=6.757),8.281(1H, d, J=0.000),3.822(t, 2H),2.791(1H, ddd, J=7.114, J=6.914),1.591(2H, d, J=6.757),1.251(3H, t, J=7.114),0.901(3H, t, J=7.114)。
图谱中,化学位移δ=1.591、1.251、0.901、2.791的为原料丁胺上甲基和亚甲基氢共振吸收峰,δ=4.011的为原料丁胺反应后形成亚胺氢的共振吸收峰,这些峰的存在证明间隔臂偶联成功,仲丁灵半抗原结构正确。
实施例2 仲丁灵抗原的制备
1、仲丁灵免疫抗原的合成
仲丁灵半抗原与牛血清白蛋白(BSA)偶联得到免疫原。
取仲丁灵半抗原11 mg,加二甲基亚砜(DMSO)0.2 mL溶解,加三乙胺20 μL,搅拌,混匀,加氯甲酸异丁酯6 mg,搅拌2 h,得到半抗原活化液A液;取50 mg BSA加0.1 mol/L pH值为7.2的PB缓冲液溶解,得到B液,将A液缓慢滴加到B液中,继续搅拌5 h,停止反应,0.02mol/L PBS透析3 d,每天换液3次,得到仲丁灵-BSA偶联物,即为免疫原,分装,-20℃保存。
2、仲丁灵包被抗原的合成
仲丁灵半抗原与卵清蛋白(OVA)偶联得到包被原。
取仲丁灵半抗原6 mg,加N,N-二甲基甲酰胺(DMF)0.2 mL溶解,加碳二亚胺(EDC)4.5 mg,搅拌,澄清,加N-琥珀酰亚胺(NHS)2.24 mg,室温搅拌活化2 h,得到A液;取OVA 50mg,加6 mL 0.05 mol/L pH值为7.2的PB缓冲液溶解,得到B液,将A液缓慢滴加到B液中,室温搅拌反应5 h,停止反应,0.02 mol/L PBS透析3 d,每天换液3次,得到仲丁灵-OVA偶联物,即为包被原,分装,-20℃保存。
3、仲丁灵抗原的鉴定
按合成仲丁灵偶联抗原反应所用半抗原、载体蛋白与偶联产物的比例,进行紫外(200~ 400 nm)扫描测定,通过比较三者分别在260 nm和280 nm的吸光度值计算其结合比。偶联物仲丁灵半抗原-载体蛋白的最大吸收峰与仲丁灵半抗原、载体蛋白的最大吸收峰相比发生了明显的变化,表明仲丁灵半抗原-载体蛋白的合成是成功的。经计算,半抗原与BSA的结合比为12:1,与OVA的结合比为9:1。
实施例3 仲丁灵单克隆抗体的制备
1、杂交瘤细胞的获得
1)首次免疫:将仲丁灵半抗原-BSA偶联物(免疫原)与等量的弗氏完全佐剂充分乳化,皮下注射6周龄的Balb/c小鼠,每只0.2 mL;
2)加强免疫两次:从首次免疫开始,每两周加强免疫一次,用弗式不完全佐剂代替弗氏完全佐剂,方法和剂量同首次免疫;
3)最后一次加强免疫一周后眼底静脉采血测效价和抑制,有抑制且效价达到1:10000以上时进行如下末次免疫:腹腔注射不加任何佐剂的免疫原溶液0.1 mL,三天后处死小鼠,取其脾脏与骨髓瘤细胞融合;
4)采用间接竞争酶联免疫分析方法测定细胞上清液,筛选阳性孔。利用有限稀释法对阳性孔进行克隆化,得到并建立稳定分泌仲丁灵单克隆抗体的杂交瘤细胞株,取处于对数生长期的杂交瘤细胞用冻存液制成细胞悬液,分装于冻存管,在液氮中长期保存。
2、单克隆抗体的制备
1)细胞复苏:取出仲丁灵单克隆抗体杂交瘤细胞株冻存管,立即放入37℃水浴中速融,离心去除冻存液后,移入培养瓶内培养;
2)制备腹水与抗体纯化:采用体内诱生法,将Balb/c小鼠(8周龄)腹腔注入灭菌石蜡油0.5 mL/只,7天后腹腔注射杂交瘤细胞5×105个/只,7天后采集腹水。用辛酸-饱和硫酸铵法进行纯化,得到仲丁灵单克隆抗体溶液(-20℃保存)。
3、单克隆抗体效价的测定
用间接竞争 ELISA法测定抗体的效价为1:(150000~400000)。
间接竞争ELISA方法:用仲丁灵半抗原-OVA偶联物包被酶标板,加入仲丁灵标准品溶液、仲丁灵单克隆抗体溶液和辣根过氧化物酶标记的羊抗鼠抗抗体溶液,25℃反应30min,倒出孔内液体,用洗涤液洗涤3~5次,用吸水纸拍干;加入底物显色液,25℃反应15 min后,加入终止液终止反应;设定酶标仪于波长450 nm处测定每孔吸光度值。
4、单克隆抗体特异性的测定
抗体特异性是指它同特异性抗原结合的能力与同该类抗原类似物结合能力的比较,常用交叉反应率作为评价标准。交叉反应越小,抗体的特异性则越高。
本实验将仲丁灵及烟草中常见的其他二硝基苯胺类除草剂(氟节胺、异丙乐灵、二甲戊灵、乙丁氟灵、氟乐灵)做系列稀释,分别与单克隆抗体进行间接竞争ELISA,制作标准曲线,分析得到IC50,然后按下式计算交叉反应率:
结果显示仲丁灵及烟草中常见的其他二硝基苯胺类除草剂的交叉反应率为:仲丁灵100%、氟节胺<1%、异丙乐灵<1%、二甲戊灵<1%、乙丁氟灵<1%、氟乐灵<1%。本发明抗体对氟节胺、异丙乐灵、二甲戊灵、乙丁氟灵、氟乐灵等常见的其他二硝基苯胺类除草剂无交叉反应,只针对仲丁灵有特异性结合。
Claims (7)
1.一种仲丁灵半抗原的制备方法,其特征在于:是由4-氯-3,5-二硝基苯乙酸与丁胺反应得到,其分子结构式为:
。
2.如权利要求1所述的仲丁灵半抗原的制备方法,其特征在于:该制备方法的具体步骤如下:
取4-氯-3,5-二硝基苯乙酸1.0 g,加50 mL乙醇溶解,加碳酸钠0.45 g,搅拌,加丁胺0.31 g,80℃油浴加热,搅拌3 h,检测,原料基本反应完全;停止反应,冷却到室温,旋蒸,除去乙醇,加80 mL水,用1 mol/L盐酸调节pH值到4,有大量浑浊,加80 mL乙酸乙酯萃取,水洗,上硅胶柱,用体积比为5:1的二氯甲烷/甲醇洗脱分离,得到仲丁灵半抗原产物1.05 g。
3.如权利要求1所述方法制备的仲丁灵半抗原的应用,其特征在于:所述仲丁灵半抗原可用于制作动物免疫的抗原体系原料。
4.一种仲丁灵抗原的制备方法,其特征在于:所述仲丁灵抗原为仲丁灵半抗原与载体蛋白的偶联物,是由权利要求1所述仲丁灵半抗原与载体蛋白偶联得到;所述载体蛋白为甲状腺蛋白、牛血清白蛋白、兔血清蛋白、人血清蛋白、卵清蛋白或血蓝蛋白。
5.如权利要求4所述的仲丁灵抗原的制备方法,其特征在于:具体步骤如下:取仲丁灵半抗原11 mg,加二甲基亚砜(DMSO)0.2 mL溶解,加三乙胺20 μL,搅拌,混匀,加氯甲酸异丁酯6 mg,搅拌2 h,得到半抗原活化液A液;取50 mg牛血清白蛋白(BSA)加0.1 mol/L pH值为7.2的磷酸盐缓冲液(PB)溶解,得到B液,将A液缓慢滴加到B液中,继续搅拌5 h,停止反应,0.02 mol/L PBS透析3天,每天换液3次,得到仲丁灵-BSA偶联物即仲丁灵抗原,分装,-20℃保存。
6.如权利要求4所述的仲丁灵抗原的制备方法,其特征在于:具体步骤如下:取仲丁灵半抗原6 mg,加N,N-二甲基甲酰胺(DMF)0.2 mL溶解,加碳二亚胺(EDC)4.5 mg,搅拌,澄清,加N-琥珀酰亚胺(NHS)2.24 mg,室温搅拌活化2 h,得到A液;取卵清蛋白(OVA)50 mg,加6mL 0.05 mol/L pH值为7.2的PB溶解,得到B液,将A液缓慢滴加到B液中,室温搅拌反应5 h,停止反应,0.02 mol/L PBS透析3天,每天换液3次,得到仲丁灵-OVA偶联物即仲丁灵抗原,分装,-20℃保存。
7.如权利要求4所述方法制备的仲丁灵抗原的应用,其特征在于:采用仲丁灵抗原免疫动物得到的单克隆抗体,可用于建立酶联免疫吸附测定方法和胶体金试纸快速测定法,从而实现烟草及食品中仲丁灵的快速检测。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811104606.4A CN109053477B (zh) | 2018-09-21 | 2018-09-21 | 一种仲丁灵半抗原与抗原的制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811104606.4A CN109053477B (zh) | 2018-09-21 | 2018-09-21 | 一种仲丁灵半抗原与抗原的制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109053477A true CN109053477A (zh) | 2018-12-21 |
CN109053477B CN109053477B (zh) | 2020-11-20 |
Family
ID=64763295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811104606.4A Active CN109053477B (zh) | 2018-09-21 | 2018-09-21 | 一种仲丁灵半抗原与抗原的制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109053477B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110551220A (zh) * | 2019-08-29 | 2019-12-10 | 北京勤邦生物技术有限公司 | 一种滴滴涕单克隆抗体的制备及其应用 |
CN113831253A (zh) * | 2021-11-04 | 2021-12-24 | 南京农业大学 | 一种二甲戊灵半抗原及其制备方法和应用 |
CN114480295A (zh) * | 2022-01-18 | 2022-05-13 | 江南大学 | 一株分泌抗仲丁灵单克隆抗体杂交瘤细胞株及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105272866A (zh) * | 2014-07-25 | 2016-01-27 | 北京维德维康生物技术有限公司 | 苯乙醇胺a半抗原、抗原及其制备方法和应用 |
CN106046143A (zh) * | 2016-07-25 | 2016-10-26 | 杭州莱和生物技术有限公司 | 一种苯胺绿人工抗原的制备方法 |
-
2018
- 2018-09-21 CN CN201811104606.4A patent/CN109053477B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105272866A (zh) * | 2014-07-25 | 2016-01-27 | 北京维德维康生物技术有限公司 | 苯乙醇胺a半抗原、抗原及其制备方法和应用 |
CN106046143A (zh) * | 2016-07-25 | 2016-10-26 | 杭州莱和生物技术有限公司 | 一种苯胺绿人工抗原的制备方法 |
Non-Patent Citations (5)
Title |
---|
KLEINSTREUER ET AL: "Environmental Impact on Vascular Development Predicted by High‑Throughput Screening High‑Throughput Screening", 《ENVIRONMENTAL HEALTH PERSPECTIVES》 * |
NISHA S. SIPES ETAL: "Predictive Models of Prenatal Developmental Toxicity from ToxCast High-Throughput Screening Data", 《TOXICOLOGICAL SCIENCES》 * |
彭方毅等: "硝基苯胺多克隆抗体的制备及鉴定", 《重庆工学院学报( 自然科学)》 * |
杨景峰等: "地乐胺的毒性及其检测技术", 《黑龙江畜牧兽医》 * |
林茹等: "半抗原免疫层析法在农药残留检测中的应用", 《广东农业科学》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110551220A (zh) * | 2019-08-29 | 2019-12-10 | 北京勤邦生物技术有限公司 | 一种滴滴涕单克隆抗体的制备及其应用 |
CN113831253A (zh) * | 2021-11-04 | 2021-12-24 | 南京农业大学 | 一种二甲戊灵半抗原及其制备方法和应用 |
CN113831253B (zh) * | 2021-11-04 | 2023-07-04 | 南京农业大学 | 一种二甲戊灵半抗原及其制备方法和应用 |
CN114480295A (zh) * | 2022-01-18 | 2022-05-13 | 江南大学 | 一株分泌抗仲丁灵单克隆抗体杂交瘤细胞株及其应用 |
CN114480295B (zh) * | 2022-01-18 | 2023-08-22 | 江南大学 | 一株分泌抗仲丁灵单克隆抗体杂交瘤细胞株及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN109053477B (zh) | 2020-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4980536B2 (ja) | ネオニコチン殺虫剤のイムノアッセイ | |
CN109232286A (zh) | 一种二甲戊灵半抗原与抗原的制备方法及应用 | |
CN100482643C (zh) | 一种氨基脲衍生物及其单克隆抗体与应用 | |
CN109111394B (zh) | 一种啶虫脒半抗原与抗原的制备方法及应用 | |
CN105807055B (zh) | 一种检测二氯喹啉酸的试纸条及其制备方法和应用 | |
CN109053477A (zh) | 一种仲丁灵半抗原与抗原的制备方法及应用 | |
CN105424939B (zh) | 一种检测多菌灵的试纸条及其制备方法和应用 | |
CN109206332A (zh) | 一种氟节胺半抗原与抗原的制备方法及应用 | |
CN109265404A (zh) | 一种多菌灵半抗原与抗原的制备方法及应用 | |
CN105785011B (zh) | 一种检测抑芽丹的试纸条及其制备方法和应用 | |
CN109265401B (zh) | 一种异菌脲半抗原与抗原的制备方法及应用 | |
CN106771137A (zh) | 检测尼卡巴嗪的酶联免疫试剂盒及其应用 | |
CN110627726B (zh) | 咪鲜胺半抗原、人工抗原和抗体及其制备方法和应用 | |
Wang et al. | Detection of triclabendazole and three metabolites in bovine muscle samples with a gold nanoparticle-based lateral flow immunoassay | |
CN106831498B (zh) | 呋喃西林代谢物sem衍生化半抗原、人工抗原的制备方法及其应用 | |
CN103288965B (zh) | 一种多氯联苯单克隆抗体的制备方法 | |
CN102507930A (zh) | 一种快速检测痕量吡虫啉残留的试剂盒 | |
CN109752531A (zh) | 一种检测鸡蛋中氟虫腈的试剂盒及其检测方法 | |
CN101962359B (zh) | 恩诺沙星半抗原、人工抗原和抗体及其制备方法和应用 | |
CN109061149A (zh) | 一种检测仲丁灵的时间分辨荧光免疫层析试纸条及其制备方法和应用 | |
CN106645764A (zh) | 检测地西泮的酶联免疫试剂盒及其应用 | |
CN108689985A (zh) | 一种黄樟素半抗原与抗原的制备方法及应用 | |
CN109061148A (zh) | 一种检测仲丁灵的试纸条及其制备方法和应用 | |
CN108997161A (zh) | 一种甲霜灵半抗原与抗原的制备方法及应用 | |
CN109324187B (zh) | 一种检测甲霜灵的酶联免疫试剂盒及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |